Human germline biallelic complete NFAT1 deficiency causes the triad of progressive joint contractures, osteochondromas, and susceptibility to B cell malignancy

Mehul Sharma<sup>1,2</sup>, Maggie P. Fu<sup>3,4†</sup>, Henry Y. Lu<sup>1,2†</sup>, Ashish A. Sharma<sup>5</sup>, Bhavi P. Modi<sup>1</sup>,
 Christina Michalski<sup>1,2</sup>, Susan Lin<sup>1</sup>, Joshua Dalmann<sup>1</sup>, Areesha Salman<sup>1</sup>, Kate L. Del
 Bel<sup>1</sup>, Meriam Waqas<sup>1</sup>, Jefferson Terry<sup>6</sup>, Audi Setiadi<sup>6</sup>, Pascal M. Lavoie<sup>1,2</sup>, Wyeth W.
 Wasserman<sup>3,7</sup>, Jill Mwenifumbo<sup>3</sup>, Michael S. Kobor<sup>3,4,7</sup>, Anna F. Lee<sup>6</sup>, Anna Lehman<sup>3</sup> on
 behalf of the CAUSES Study, Sylvia Cheng<sup>1</sup>, Anthony Cooper<sup>9</sup>, Millan S. Patel<sup>3</sup>, Stuart
 E. Turvey<sup>1,2</sup>

- <sup>1</sup>Department of Pediatrics, BC Children's Hospital, The University of British Columbia,
- 11 Vancouver, British Columbia, Canada
- <sup>2</sup>Experimental Medicine Program, Faculty of Medicine, The University of British
- 13 Columbia, British Columbia, Canada
- <sup>3</sup>Department of Medical Genetics, BC Children's Hospital Research Institute, University
- of British Columbia, Vancouver, British Columbia, Canada
- <sup>4</sup>Genome Science and Technology Program, Faculty of Science, The University of
- 17 British Columbia, Vancouver, British Columbia, Canada
- <sup>5</sup>Department of Pathology, Emory University, Atlanta, GA, USA
- <sup>6</sup>Department of Pathology and Laboratory Medicine, BC Children's Hospital, Vancouver,
- 20 British Columbia, Canada

1

2

3

2425

26 27

28

31

32

35

- <sup>7</sup>Centre for Molecular Medicine and Therapeutics, Vancouver, British Columbia, Canada
- <sup>8</sup>Department of Orthopaedics, Faculty of Medicine, University of British Columbia
- <sup>†</sup>These authors contributed equally.

Correspondence to: Stuart E. Turvey, MBBS, DPhil, FRCPC

BC Children's Hospital 950 West 28<sup>th</sup> Avenue

Vancouver, BC, V5Z 4H4, Canada Phone: 604 875 2345 ext. 5094

Email: <u>sturvey@cw.bc.ca</u>

33 **Word Count:** 4000

34 **Abstract:** 150

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

**Acknowledgements:** This work was supported by grants from the Canadian Institutes of Health Research (PJT 178054) (S.E.T.), Genome British Columbia (SIP007) (S.E.T.), and BC Children's Hospital Foundation. S.E.T. holds a Tier 1 Canada Research Chair in Pediatric Precision Health and the Aubrey J. Tingle Professor of Pediatric Immunology. M.S. is supported by a CIHR Frederick Banting and Charles Best Canada Graduate Scholarships Doctoral Award (CGS-D) and University of British Columbia Four Year Doctoral Fellowship (4YF). H.Y.L. is supported by a CGS-D, 4YF, Killam Doctoral Scholarship, Friedman Award for Scholars in Health, and a BC Children's Hospital Research Institute Graduate Studentship. Investigators in the CAUSES Study include: Shelin Adam, Nick Dragojlovic, Christèle du Souich, Alison M. Elliott, Anna Lehman, Larry Lynd, Jill Mwenifumbo, Tanya N. Nelson, Clara van Karnebeek, and Jan M. Friedman. We would like to acknowledge Navdeep Sangha at Thomas Jefferson University Hospital for providing his expertise in B cell lymphomas. We would also like to acknowledge the histology labs at BC Children's Hospital and BC Cancer for their assistance in histological and immunohistochemistry, and the Biomedical Research Centre Sequencing Core (BRC-Seq) for their assistance with RNA-Sequencing and processing.

#### **ABSTRACT**

54

Discovery of humans with monogenic disorders has a rich history of generating new 55 insights into biology. Here we report the first human identified with complete deficiency 56 of nuclear factor of activated T cells 1 (NFAT1). NFAT1, encoded by NFATC2, mediates 57 58 calcium-calcineurin signals that drive cell activation, proliferation, and survival. The patient is homozygous for a damaging germline NFATC2 variant 59 (c.2023 2026delTACC; p.Tyr675Thrfs\*18) and presented with joint contractures, 60 osteochondromas, and B cell lymphoma. Absence of NFAT1 protein in chondrocytes 61 62 caused enrichment in pro-survival and inflammatory genes. Systematic single-cell-omic analyses revealed an environment that promotes lymphomagenesis with accumulation 63 of naïve B cells (with oncogenic signatures - MYC, JAK1), exhausted CD4<sup>+</sup> T cells, 64 impaired T follicular helper cells, and aberrant CD8<sup>+</sup> T cells. This work highlights the 65 pleiotropic role of human NFAT1, will empower the diagnosis of additional patients with 66 67 NFAT1 deficiency, and further define detrimental effects a long-term use of calcineurin inhibitors. 68

#### INTRODUCTION

69

Intracellular calcium signaling orchestrates a diverse range of critical physiological and 70 immunological processes, including lymphocyte activation, differentiation, and effector 71 function<sup>1, 2</sup>. T cell receptor (TCR) or B cell receptor (BCR) engagement activates 72 phospholipase C (PLC), generating inositol-1,4,5-triphosphate (IP3), which, in turn, 73 activates IP3 receptors and creates an influx of Ca<sup>2+</sup> from the endoplasmic reticulum 74 into the cytosol<sup>2</sup>. Free Ca<sup>2+</sup> is subsequently bound by calmodulin, resulting in a 75 conformation change that promotes binding of the serine/threonine phosphatase 76 calcineurin<sup>3, 4</sup>. This calmodulin-calcineurin interaction activates an array of transcription 77 factor families, including the nuclear factor of activated T cells (NFAT) family. This 78 family consists of five members: NFAT1 (NFATc2, NFATp), NFAT2 (NFATc1, NFATc), 79 NFAT3 (NFATc4), NFAT4 (NFATc3, NFATx) and NFAT5<sup>5</sup>. These proteins contain an N-80 terminal transactivation domain (TAD), a regulatory NFAT homology region (NHR), a 81 DNA-binding domain (REL-homology domain, [RHD]) and a carboxy-terminal domain. 82 Activation of NFAT1-4 is dependent on calcineurin-mediated dephosphorylation of the 83 NHR, which exposes a nuclear localization signal and leads to NFAT translocation to be 84 nucleus and transcriptional regulation<sup>5, 6, 7, 8, 9, 10, 11, 12</sup>. 85 86 Originally discovered in activated T cells as a protein complex that binds the interleukin-2 (IL-2) promoter<sup>13</sup>, our understanding of the NFAT family has grown remarkably over 87 the past few decades. It is now appreciated that NFATs have a role in the differentiation 88 and activation of many T helper subsets, including T<sub>H</sub>1, T<sub>H</sub>2, T<sub>H</sub>17, T follicular helper 89 cells (T<sub>FH</sub>), and T regulatory cells (Tregs)<sup>14, 15</sup>. NFATs are also expressed by and have a 90 function in other immune cells including B cells<sup>16</sup> and dendritic cells<sup>17</sup>, as well as in non-91 immune cells, such as cartilage cells<sup>18, 19, 20</sup>, adipocytes<sup>21</sup>, cardiac cells<sup>22</sup> and breast 92 cancer cells<sup>23</sup>. Despite our expanded understanding of this transcription factor family. 93 the specific function of each individual NFAT protein has been difficult to define fully due 94 to the redundancy amongst the family members. This is due to highly homologous 95 RHDs, which all bind to a core DNA sequence of (A/T)GGAAA<sup>11</sup>. On the other hand, 96 their non-redundant roles are attributed to their interaction with other transcription 97 factors via their dissimilar TADs<sup>24</sup>. Furthermore, NFATs can also alter the function of 98

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

other transcription factors by directly competing for binding sites, as has been reported with nuclear factor kappa B (NF-κB)<sup>25</sup>. A particularly illustrative example of how critical calcineurin and NFATs are in immunity and clinical medicine is the fact that calcineurin inhibitors (e.g. cyclosporin A (CsA), tacrolimus [FK506], and pimecrolimus), which suppress T cells without significant myelotoxicity, have served as the standard of care over the past 40 years for preventing organ rejection and graft-versus-host disease in transplant recipients 10, 26, 27, 28. Further, they have also been used successfully to treat a variety of immune-mediated disorders including atopic dermatitis, psoriasis, rheumatoid arthritis, and uveitis<sup>28, 29</sup>. However. despite the effectiveness of calcineurin inhibitors, serious adverse side effects have been reported, including nephrotoxicity, lymphomas, and increased susceptibility to infections<sup>30</sup>. Insight into NFAT biology in humans is thus critical to understand the mechanisms underlying the side-effects of these drugs. One strategy to study human NFAT biology has been to use calcineurin inhibitors<sup>31</sup>. However, since they inhibit all members of the NFAT family, the role of individual members has been challenging to define. Similarly, although targeted genetic disruption of individual NFAT family members in mice has helped uncover their specific functions in murine immunity, this approach is not fully transferable to the human system. A powerful complementary approach is to identify and study rare individuals who carry damaging germline variants in genes encoding members of the NFAT family, allowing us to investigate their roles in an unmodified human system. Here, we report the identification and characterization of the first human with complete NFAT1 deficiency.

#### **METHODS**

122

123

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

### Study participants and consent

- All study participants and/or their parents/guardians provided written informed consent
- to participate. All individuals also provided consent to be published. Research study
- protocols (H18-02853 and H15-00092) were approved by The University of British
- 127 Columbia Clinical Research Ethics Board.

## Identification of variant and confirmation by Sanger sequencing

Trio whole exome sequencing (WES) was performed on genomic DNA from the patient and both parents on an Illumina platform at Ambry Genetics (Aliso Viejo, California, USA) after capture of targeted regions using xGen™ Exome Hybridization Panel (IDT, Coraville, Iowa, USA). More than 99% of targeted regions were covered by at least 10 reads that averaged 150 bp in length. Reads were aligned to GRCh37/Hg19 and variants were called using BWA-MEM, GATK 3.5-0, SAMtools 0.1.19, and Picard 1.139, and then annotated and prioritized with VarSeg v.1.5 (Golden Helix, Bozeman, Montana, USA). WES data was analyzed using an updated version of our in-house. open-source, semi-automated bioinformatics pipeline that has been previously described<sup>32,</sup> Α predicted null NFATC2 variant (c.2023 2026delTACC, p.Tyr675Thrfs\*18) was selected for further analysis on the basis of: i) the clinical phenotype matching closely to that of Nfatc2 knockout mice<sup>18, 34</sup>; ii) the variant resulting in a premature stop codon; and iii) the variant segregating with the disease in the extended family. The variant was confirmed by standard Sanger sequencing of genomic DNA from all individuals of the family. Briefly, genomic DNA was extracted from whole blood (QIAmp DNA Blood Mini Kit; Qiagen, Hilden, Germany) and buccal swabs (DNeasy Blood and Tissue Kit; Qiagen) according to manufacturer's recommendations. The variant region was PCR amplified using GoTaq Green Master Mix (Promega; Madison, Wisconsin, USA) and primers that flank the area: 5'-AACACCCATTAGACAGTGGGC-3' CAGGGACAGGAGTCATCCAC-3'; Reverse:

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

(Integrated DNA Technologies; Coralville, Iowa, USA). The PCR product was purified using a QIAquick PCR Purification Kit (Qiagen) and sequenced using the same primers. Cell isolation, culture, and immortalization of lymphoblastoid cell lines (LCLs) Peripheral blood mononuclear cells (PBMCs) were isolated by standard Ficoll-Paque (GE Healthcare, Chicago, Illinois, USA) density centrifugation from four discrete blood draws and time points from the patient over a span of two years, one time point from four heterozygous family members, and from eight unique age-matched healthy controls. PBMCs were cultured in complete RPMI-1640 (GE Healthcare) supplemented with 10% heat inactivated FBS (Gibco, Life Technologies; Rockville, Maryland, USA), 2mM L-glutamine (HyClone, Thermo Fisher Scientific; Waltham, Massachusetts, United States), and 1mM sodium pyruvate (Gibco, Life Technologies; Carlsbad, California, USA) in the presence or absence of various stimuli described in the following sections. Lymphoblastoid cell lines (LCLs) were derived by EBV transformation and cultured in complete RPMI-1640 as previously described by our group<sup>35, 36</sup>. Briefly, PBMCs from the patient (II-1), one heterozygous control (II-2), and one healthy control individual were cultured in complete RPM1-1640 media (GE Healthcare) supplemented with tacrolimus (AG Scientific, San Diego, California) for 1 h. Cells were then infected with supernatant from a viral replication-permissive marmoset cell line B95-8 (ATCC, Manassas, Virginia, USA) until sufficient B cell blasts were generated. LCLs were cultured in complete RPMI-1640 media without tacrolimus. Chondrocytes were grown from an osteochondroma that was surgically removed from the patient's proximal tibia. The small cartilage component was excised from connective tissue and placed in separate wells in a 6-well plate and digested with 200 U/ml collagenase in complete Dulbecco's Modified Eagle Medium (DMEM; GE Healthcare) supplemented with 10% heat inactivated FBS (Gibco, Life Technologies, Rockville, Md), 2mM L-glutamine (HyClone, Thermo Fisher Scientific), and 1mM sodium pyruvate (Gibco, Life Technologies) and 1x Antibiotic-Antimycotic (Gibco, Thermo Fisher) for 1

day at 37°C. Cells were filtered with a 40µM cell strainer and seeded in a monolayer and allowed to adhere. Stable expression of NFAT1 using a Lentivirus vector Stable expression of NFAT1 was established as previously described<sup>37, 38</sup>. Briefly, the NFATC2 (NM\_173091) gene was cloned out of a Myc-DDK-tagged NFATC2 plasmid (Cat#: RC213966, OriGene Technologies; Rockville, Maryland, USA) and cloned into a GFP-tagged Lenti vector (Cat#: PS100071, OriGene Technologies) using EcoRI-HF (Cat#: R3101) and Notl-HF (Cat#: R3189), both from New England BioLabs (Ipswich, Massachusetts, USA). GFP-tagged NFATC2 and GFP-expressing empty vector (EV) were packaged using 3rd generation packaging plasmids, and transfected into HEK 293T cells. Culture media was collected, centrifuged, filtered, concentrated, and stored at -80°C before use. To establish patient-derived chondrocytes that stably express WT NFAT1, chondrocytes were infected with EV or WT NFATC2 lentiviral particles and 5ug/ml polybrene (Sigma-Aldrich, St Louis, Mo), cultured, and expanded in high glucose DMEM (HyClone) supplemented with 10% FBS and 2mM<sub>1</sub>-glutamine. Expanded cells were sorted on GFP expression using a BD FACS Aria (BD Biosciences) cell sorter. To establish patient T cells that express WT NFAT1, isolated PBMCs were stimulated with CD3/CD28 T cell activator (Cat#: 10971; Stemcell, Vancouver, Canada) for 3 days, infected with EV or WT NFATC2 particles for 24 hours at 37°C, and stimulated with CD3/CD28 T cell activator for another 3 days before undergoing downstream flow cytometric analyses.

## Cytometric Bead Array (CBA)

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

A cytokine bead array was used to measure cytokine production in chondrocytes as previously described<sup>39</sup>. Briefly, patient and WT-*NFATC2*-transduced chondrocytes were seeded in T25 flasks in complete DMEM media (GE Healthcare) without antibiotics and

allowed to reach confluency. Chondrocytes were washed and subsequently left untreated in media alone or stimulated with 50ng/mL phorbol 12-myristate 13-acetate (PMA) (Sigma) and 1 $\mu$ M ionomycin (Sigma) (P/I) or 20ng/mL IL-1 $\beta$  (Cat#: 14-8018-62; eBiosciences, San Diego, California, USA) at 37°C for 24h. Supernatants were collected and a human inflammatory cytokine CBA kit was used to measure the concentration of IL-6 (BD Biosciences, Cat#: 552932; Franklin Lakes, New Jersey, USA) according to manufacturer's recommendations<sup>40</sup>. Samples were acquired using a

BD LSRII flow cytometer and analyzed using FlowJo (BD Biosciences).

## Immunoblotting

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

Changes in NFAT1 expression and phosphorylation status was detected by stimulating LCLs with 10μM ionomycin for 10 min in complete RPMI or empty vector (EV)- or WT-NFATC2-transduced chondrocytes with P/I or 20ng/mL IL-1ß for 15 min in complete DMEM at 37°C. Whole cell lysates were prepared by lysing untreated and stimulated LCLs or chondrocytes in a modified radio immunoprecipitation assay buffer with the Halt protease and phosphatase inhibitors cocktail (Thermo Fisher Scientific). Lysates were separated by 10% SDS-PAGE and transferred onto polyvinylidene difluoride membranes (Immobilon-FL; MilliporeSigma. Billerica, Massachusetts. USA). Membranes were blocked with 5% BSA in Tris-buffered saline with Tween-20, incubated with primary antibodies for 18h at 4°C, incubated with secondary antibodies for 1h at room temperature, and imaged using a LI-COR Odyssey infrared scanner (LI-COR Biosciences, Lincoln, Nebraska, USA). The primary antibodies used were the following: NFAT1 (Cat#: 4389) and β-actin (Cat#: 3700) both from Cell Signaling Technologies (Danvers, Massachusetts, USA). The secondary antibodies used were the following: goat anti-rabbit IgG DyLight 800 conjugated (611-145-002-0.5; Rockland Immunochemicals, Pottstown, Pennsylvania, USA) and goat anti-mouse IgG IRDye 680RD (926-6870; LI-COR).

# Quantification of NFATC2 transcript abundance by quantitative PCR (qPCR)

- qPCR was conducted as previously described<sup>35</sup>. Briefly, total RNA was extracted from
- unstimulated or 18h ionomycin-stimulated LCLs using a RNeasy Plus Mini Kit (Qiagen)
- and converted to cDNA using an iScript cDNA synthesis kit (BioRad Laboratories;
- Hercules, California, USA). Transcript abundance was measured using a Universal
- SYBR Green Super Mix (Bio-Rad) and a 7300 Real-Time PCR System (Applied
- Biosystems, Foster City, California, USA). The primers used for *NFATC2* were the
- following: Forward: 5'-GTCAGCCTCAGCACTTTACC-3'; Reverse: 5'-
- 242 ATCAGAGTGGGGTCATATTCATC -3' (PrimeTime; Integrated DNA Technologies).
- Relative transcript abundance was quantified relative to *ACTB* using the 2<sup>-ΔΔCT</sup>
- 244 method<sup>41</sup>.

246

## **RNA-Sequencing**

- To investigate the global transcriptome, EV- or WT-NFATC2-transduced chondrocytes
- were unstimulated, 4h P/I-stimulated, or 4h 20ng/mL IL-1β-simulated. RNA was
- extracted in triplicate as previously described<sup>35</sup> using a RNeasy Mini Plus Kit (Qiagen)
- according to manufacturer's recommendations. RNA was prepared following the
- standard protocol for the NEBNext Ultra II Stranded mRNA (New England Biolabs) and
- sequenced on the Illumina NextSeq 500 with Paired End 42 bp x 42 bp reads. De-
- 253 multiplexed read sequences were aligned to a reference sequence using Spliced
- Transcripts Alignment to a Reference (STAR) aligner. E1 Assembly and expression
- were estimated using Cufflinks E2 through bioinformatics apps on Illumina BaseSpace.
- Expression data were normalized to reads between samples using the edgeR package
- in R (R Foundation, Vienna, Austria). Normalized counts were filtered to remove low
- counts using the filterByExpr function in edgeR<sup>42</sup>. Batch correction and differential
- expression was conducted using Limma<sup>43</sup>. Pathway analysis was done by first
- performing Gene Set Enrichment Analysis (GSEA) with 1000 permutations using the
- Molecular Signatures Database Hallmark module. Signal-to-noise ratio was used for
- gene ranking and the obtained NESs and P-values were further adjusted using the
- Benjamini-Hochberg method. Pathways with an adjusted P-value < 0.05 were
- considered significant. Leading edge genes from significant pathways between EV and

265 WT-NFATC2-transduced chondrocytes were identified. Expression levels of these genes were then determined in each group. 266 Sample level enrichment analyses (SLEA) scores were computed as previously 267 described<sup>44</sup>. Briefly, z-scores were computed for gene sets of interest for each sample. 268 The mean expression levels of significant genes were compared to the expression of 269 1000 random gene sets of the same size. The difference between observed and 270 expected mean expression was then calculated and represented on heatmaps 271 generated using Morpheus (https://software.broadinstitute.org/morpheus). Raw data are 272 273 deposited on Gene Expression Omnibus at the following accession number

## Single Cell RNA-Sequencing

GSE193414.

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

Targeted single cell RNA-Sequencing of 500 curated immune-related genes was conducted on PBMCs from the patient, three heterozygous controls, and two agematched healthy controls using the BD Rhapsody Single Cell platform, the Rhapsody Cartridge Reagent Kit (BD, Cat#: 633731), the BD Rhapsody Cartridge Kit (BD, Cat#: 633733), the Rhapsody cDNA Kit (BD, Cat#: 633733), the Rhapsody Targeted mRNA amplification Kit (Cat#: 633774), and the Human Single-Cell Multiplexing Kit (BD, Cat#: 633781) according to manufacturer's recommendations. Briefly, thawed PBMCs were rested overnight and stimulated with P/I or left untreated for 4h. Cells from each donor were labelled with sample tags, washed with stain buffer and pooled together in cold sample buffer to obtain ~25,000 cells in 620ul for each of the unstimulated and stimulated samples. Two nanowell cartridges were primed and subsequently loaded with the pooled samples for 15min at room temperature on the Rhapsody Express instrument (BD, Cat#: 633702). Cell capture beads were prepared and loaded onto the cartridge. The cartridge was washed, cells were lysed, and beads were retrieved. The sample then underwent reverse transcription and exonuclease I treatment. cDNA was amplified using a custom immune panel (Supp. Table 5) via PCR. mRNA PCR products were separated from sample tag products with double-sided size selection using AMPure beads (Beckman Coulter, Cat#: A63880). Separated products were further

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

amplified by PCR and then purified using AMPure beads. Product quality was checked using Agilent DNA High Sensitivity Kit (Agilent Technologies, Cat#: 5067-4626) on the Agilent 2100 Bioanalyzer (Agilent Technologies, Cat#: G2940CA). PCR products were then PCR amplified using two index primers, one for unstimulated (5'-CGAGGCTG-3') and one for stimulated (5'-AAGAGGCA-3') samples. Indexed products were again purified using AMPure beads and sample quality was checked using the Agilent 2100 Bioanalyzer. Libraries were diluted to 650pM and multiplexed for paired-end (2 x 115bp) sequencing on a NextSeq2000 Sequencing System (Illumina) at 200 cycles P3 for 1.1 billion reads. FASTQ files were processed using the BD Rhapsody Targeted Analysis Pipeline and Seven Bridges (www.sevenbridges.com) according to manufacturer's recommendations. Briefly, R1 and R2 reads were filtered based on read length, quality, and highest single nucleotide frequency. R1 reads are annotated to identify cell labels, unique molecular identifiers (UMI), and filtered for >6 Poly(T) tail. Bowtie2 version 2.2.9 was used to map the R2 reads to the reference sequences. All reads, R1 and R2, with the same cell label, UMI sequence, and gene were collapsed into a single molecule. Recursive substation error correction (RSEC) and distribution-based error correction (DBEC) were used to adjust for PCR errors in UMI sequences (which can give rise to artifacts). Putative cells were determined by considering all reads associated with DBEC-adjusted molecules. The minimum second derivative along the cumulative reads curve is identified as the inflexion point, after which the cells are labelled as noise. Filtered putative reads that align to a sample tag sequence were used to identify sample labels for a cell. Finally, labelled DBEC-adjusted molecule counts were obtained in a CSV format for downstream analyses. The R package Seurat<sup>45</sup> was utilized for all downstream analysis. No gene per cell cutoffs were imposed since we were using a targeted 500-gene panel. Scaling and clustering was performed on each pool of samples independently. Dimensionality reduction using PCA was based on all 500 genes and UMAP was based on the first 20 PCs. Cell identities were first annotated with SingleR using fine labeling from the Novershtern hematopoietic dataset<sup>46, 47</sup>. The annotation was refined manually based on

the UMAP clustering patterns, grouping the SingleR labels into 8 main populations:

Naïve B cells, Memory B cells, Naïve CD4<sup>+</sup>, Memory CD4<sup>+</sup>, Memory CD8<sup>+</sup>, Monocytes,

NK cells, and undefined. For differential gene expression analyses, we utilized the

Seurat implementation of negative binomial test, assuming an underlying negative

binomial distribution in RNA-Seq data while leveraging the UMI counts to remove

technical noise<sup>48, 49</sup>. Raw data are deposited on Gene Expression Omnibus at the

following accession number GSE193410. All downstream analysis scripts used in

analysis are available on GitHub (https://github.com/maggie-fu/NFATC2\_RNAseq/).

## Lactate Dehydrogenase (LDH) Assay

Chondrocyte resistance to cell death was quantified using a lactate dehydrogenase assay (LDH) according to manufacturer's instructions (Promega, Cat#: G1780). Briefly, EV- or WT-NFATC2-transduced chondrocytes were seeded in 96-well plates at a concentration of 5000 cells/well. Cells were rested until they reached confluency and subsequently stimulated with P/I over a time course, including 0, 2, 4, 6, 8, 10, and 12 days at 37°C. 50 µI of cell supernatants were collected, added to 50µI of CytoTox96 reagent, and incubated in the dark for 30 min at room temperature. The reaction was subsequently stopped with 50µI of stop solution. Maximum LDH release was measured at each time point by lysing cells. Absorbance was measured on the Infinite M200 plate reader (Tecan; Männedorf, Switzerland) at 492nm. Cell death was defined as a percentage of maximum LDH release.

## B cell expansion and differentiation

Naïve B cells were isolated from PBMCs of the patient, one heterozygous family member and 6 healthy controls using the EasySep Human Naïve B Cell Isolation Kit (Cat#: 17254; Stemcell) according to manufacturer's recommendations. Cells were stained with the 'Plasmablast Differentiation' panel (**Supp. Table 6**) described in the

'Flow Cytometry' section before and after stimulation with ImmunoCult-ACF Human B

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

Cell Expansion Supplement (Cat#: 10974; Stemcell) for 6 days in order to determine the proportion of different subsets by flow cytometry. **Clinical-Grade Flow Cytometry** Patient clinical immunophenotyping was also carried out at an accredited clinical flow cytometry laboratory. Whole blood was collected and stained using DURAClone tubes (Beckman Coulter; Brea, California, USA) according to the manufacturer's recommendation. Briefly, fresh blood was incubated with dried reagent tubes and incubated in the dark at room temperature for 15 min. Cells were washed in 3mL of PBS 2 times, before being fixed in 500uL of PBS containing 0.1% formaldehyde and subsequently acquired. Panels focused on the analysis of T cell subsets (DURAClone IM T Cell Subsets, Beckman Coulter; Cat#: B53328) and B cell subset (DURAClone IM B Cell, Beckman Coulter; Cat#: B53318). All flow data were acquired on a Navios flow cytometer and then analyzed using Kaluza software (Beckman Coulter). **Research-Grade Flow Cytometry** To carry out immunophenotyping and intracellular cytokine detection, PBMCs from the patient, heterozygous family members, and age-matched controls were stimulated with P/I for 4h at 37°C in the presence of GolgiStop (Cat# 554724, BD Biosciences). Following stimulation, cells were stained with a cocktail of antibodies against surface markers for 20 min on ice then fixed with the Foxp3 Fixation/Permeabilization working solution (Cat#: 00-5123-43; Invitrogen, Thermo Fischer Scientific) from the eBioscience Foxp3 Transcription Factor Staining Buffer Set (Cat# 00-5523-00, Invitrogen, Thermo Fisher Scientific) for 20 min. Fixed cells were then stained with antibodies directed against intracellular cytokines or transcription factors for 45 min in 1x Permeabilization Buffer (Cat#: 00-8333-56; Invitrogen, Thermo Fischer Scientific). Samples were then washed and analyzed on the BD FACSymphony flow cytometer (BD Biosciences). Data were analyzed using FlowJo software (BD Biosciences). Antibody panels used for staining are listed in Supp. Table 6.

Formalin-fixed, paraffin-embedded lymph node tissue was sectioned at  $4\mu M$  and subjected to routine hematoxylin and eosin (H&E) staining or immunohistochemistry (IHC). The following IHC antibodies were used: CD21 (IF8, Dako), CD20 (L26, Ventana), BCL6 (P6-B6P, Dako), CD30 (Ber-H2, Ventana), and BCL2 (124, Dako). CD21, BCL6, and BCL2 IHC were performed on the Dako Autostainer. CD20 and CD30 IHC were performed on the Dako Omnis Automated Slide Stainer.

Clinical features of complete human NFAT1 deficiency

#### RESULTS

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

The patient (designated II-1 on the family pedigree) is born to consanguineous parents. After a healthy birth, the patient started developing difficulty bending his knees with no associated swelling, pain, erythema, or morning stiffness in early childhood (ages 0-5 years). Insidiously, many joints developed a similar painless decreased range of motion causing difficulty with ambulation. Medical care was disjointed until the patient was in his teenage years (ages 15-20 years). Assessment then demonstrated a neurodevelopmentally normal young man with marked bilateral fixed flexion contractures of knees, hips, and ankles. Multiple upper limb joints also demonstrated reduced range of motion, including wrists, hands, and shoulders (Fig. 1A, Table 1). Muscle strength and deep tendon reflexes were all intact. The joint changes significantly impacted his gait, causing him to walk with an increased anterior pelvic tilt, and leading to decreased dynamic hip range of motion with particularly diminished extension through mid to late stance. He also had diminished dynamic knee range of motion with knee flexion throughout stance and swing and mild equinus bilaterally at his ankles (Supp. Table 1). He had absent distal digital creases and prominent fetal fat pads on all fingers. Echocardiography showed a mildly hypertrophied left ventricle with multiple cords and an appearance of coarse trabeculae on the septal and free wall surfaces. Dual-energy X-ray absorptiometry (DEXA) scanning revealed low total body bone mineral density (0.888 g/cm<sup>2</sup>, z-score for chronologic age being -1.9 [-0.4 after adjusting for height]). X-rays showed flattening of multiple lower thoracic and lumbar vertebral bodies suggesting mild vertebral compression fractures. Two osteochondromas/exostoses were also identified; one on the medial aspect of the right proximal tibial metaphysis (2cm) and a second on the anterior aspect of the right proximal fibula (3cm) (Fig. 1A, 1B). In summary, the main musculoskeletal findings are contractures of the large and small joints of the upper and lower limbs. osteochondromas, and osteopenia (Table 1). In his late teens (ages 15-20 years), the patient presented with abdominal pain, fever, night sweats and weight loss (i.e. B symptoms) and was ultimately diagnosed B-cell

lymphoma, unclassifiable, with features intermediate between diffuse large B-cell

lymphoma (DLBCL) and classic Hodgkin lymphoma (cHL). Lymphoid tissue biopsy

showed effacement of typical node architecture and the absence of clear germinal

centers and follicular structure. There was a prominent population of larger atypical

lymphocytes (CD79a<sup>+</sup>CD30<sup>+</sup>CD20<sup>+</sup>CD15<sup>-</sup>BCL6<sup>+</sup>) in the background of mature CD4<sup>+</sup> and

427 CD8<sup>+</sup> T cells (**Fig. 1C**). He was staged as Ann Arbor stage 4B with widespread disease,

including abdominal, inguinal, hepatic, splenic, paratracheal, and subcarinal

lymphadenopathy. The patient was treated with 6 cycles of a modified dose-adjusted

430 EPOCH-R regimen without vincristine and went into full remission.

### Whole-exome sequencing (WES) reveals a novel damaging homozygous variant

#### in NFATC2

423

424

425

428

429

431

432

433

435

436

437

438

441

442

445

446

447

448

449

450

451

Given the unique phenotype of the patient, consanguinity, and significant family history,

we performed whole exome sequencing (WES) to identify a potential genetic etiology.

The patient was found to carry a previously unreported homozygous 4-base pair

deletion in exon 8 of the gene nuclear factor of activated T cells 2 (NFATC2) encoding

the NFAT1 transcription factor. This variant causes a frameshift leading to a premature

439 stop codon (NM 173091:c.2023 2026delTACC; NP 775114:p.Tyr675Thrfs\*18).

Sanger sequencing of the variant region in whole blood confirmed that it segregated

with disease within the patient family (Fig. 1D, 1E). The variant localizes to the DNA

binding domain of the NFAT1 protein and affects an evolutionarily conserved region

443 (**Fig. 1F**).

This variant led to significantly reduced *NFATC2* transcript abundance in patient-derived

lymphoblastoid cell lines (LCLs) when compared to heterozygous control- and unrelated

control-derived LCLs (Fig. 1G). To investigate the impact on NFAT1 protein function,

we measured NFAT1 expression in LCLs pre- and post-stimulation with the NFAT1

activator, ionomycin (Fig. 1H), and in the absence or presence of the calcineurin

inhibitor tacrolimus (FK506). We confirmed that NFAT1 expression was undetectable in

patient LCLs, but reduced in heterozygous control LCLs (Fig. 11). Furthermore, NFAT1

was strongly dephosphorylated in both wild-type and heterozygous control LCLs

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

following ionomycin stimulation and this effect was effectively inhibited by FK506 treatment (Fig. 1G, 1I). NFAT1-deficient patient chondrocytes are more enriched in cell proliferation and inflammatory genes with elevated IL-6 production and resistance to cell death Informed by the patient's joint contractures and osteochondromas, we assessed the impact of NFAT1 deficiency on chondrocytes isolated from the excised tibial osteochondroma. Patient chondrocytes had undetectable NFAT1 expression (Fig. 2A). To study the impact of NFAT1 deficiency on chondrocytes, we engineered a WT NFATC2 lentivirus construct and transduced patient chondrocytes to rescue NFAT1 expression. This restored function to the pathway as demonstrated by NFAT1 dephosphorylation that was sensitive to FK506 inhibition (Fig. 2A). Further, treatment with IL-1β, a key cytokine involved in cartilage damage in arthritis<sup>50</sup>, did not change NFAT1 phosphorylation status. To define the impact of NFAT1 deficiency on the global transcriptome of chondrocytes. we conducted bulk RNA-Seq on empty vector (EV) or WT NFATC2 -transduced patient chondrocytes untreated or stimulated with P/I or IL-1\u00ed. We identified 187 significantly upregulated and 146 significantly downregulated genes between P/I-stimulated WT NFATC2- and EV-transduced chondrocytes, which may represent NFAT1 suppressed and enhanced genes, respectively (**Fig. 2B, 2C**). Gene set enrichment analysis (GSEA) identified significant enrichment in pathways involved with cellular growth and inflammation (Fig. 2D). Notable was the enrichment of cell proliferation pathways both at baseline and in response to P/I stimulation in NFAT1-deficient EV-transduced chondrocytes, including G2/M Checkpoint (unstimulated: NES=1.790, FDR<0.001; P/I stimulated: NES=1.544, FDR=0.047) and E2F targets (unstimulated: NES=1.704, FDR=0.004; stimulated: NES=1.667, FDR=0.013) (Fig. 2D). To assess the functional consequences of these transcriptomic findings, we stimulated EV- and WT NFATC2transduced chondrocytes over a time course up to 12 days with P/I and monitored cell survival. Here, we discovered that EV-transduced NFAT1-deficient chondrocytes were

481 significantly more resistant to cell death than WT NFATC2-transduced chondrocytes 482 (Fig. 2E). The IL-6-JAK-STAT3 signaling pathway was also significantly enriched in unstimulated 483 EV-transduced NFAT1-deficient chondrocytes (NES=1.543, FDR=0.035) (Fig. 2D). 484 485 Confirming this at the protein level, both unstimulated and P/I-stimulated EV-transduced NFAT1-deficient chondrocytes produced significantly more IL-6 than 'rescued' WT-486 487 transduced chondrocytes (Fig. 2F). Taken together, these findings suggest that NFAT1 regulates chondrocyte growth, death, and proinflammatory transcriptional programs, 488 489 collectively leading to aberrant connective tissue homeostasis. 490 NFAT1 deficient B cells are largely naïve ex vivo and express proliferation 491 492 markers Given that NFAT1 is expressed in most lymphocytes<sup>16</sup>, we conducted targeted single 493 cell RNA-Sequencing (scRNA-Seq) on patient PBMCs alongside 5 healthy controls (2 494 age-matched sex-matched healthy controls and 3 heterozygous family members) 495 stimulated with P/I to identify cell type-specific defects. Unsupervised clustering analysis 496 revealed markedly reduced memory B cells and elevated memory CD4<sup>+</sup> T cells in the 497 patient PBMCs (Fig. 3A). 498 499 Since patient B cells were largely naïve, we focused our differential gene expression (DE) analysis on patient and control naïve B cells (Fig. 3B). We discovered significantly 500 501 increased transcript abundance of pro-survival, proliferation, and anti-apoptotic genes frequently associated with lymphoma in patient cells compared to controls. This 502 includes  $MYC^{51}$ ,  $HIF1A^{52}$ , JAK1,  $STAT3^{53}$ ,  $TNFAIP8^{54}$ , and  $PIK3AP1^{55}$  (**Fig. 3C**). 503 Consistent with the documented NFAT1 deficiency, classical NFAT1 targets such as 504 TNF and LTA<sup>56, 57</sup> were significantly decreased in patient naïve B cells. 505 To study this B cell phenotype further, we carried out multi-parameter flow cytometric 506 507 analyses on PBMCs from the patient, 4 heterozygous healthy family member, and 8 healthy controls (see Supp. Fig. 1A for gating strategy). Direct detection of NFAT1 508 protein confirmed the lack of NFAT1 in patient B cells as compared to controls (Fig. 509

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

**3D**). Validating our scRNA-Seg data, and consistent with clinical-grade flow cytometry (Supp. Table 2), patient B cells showed signs of a developmental arrest, with significantly elevated transitional B cells (Fig. 3E, 3F) and naïve B cells (Fig. 3G, 3I) with a concurrent reduction in class-switched memory B cells (Fig. 3G, 3H). Interestingly, despite the reduced frequency of memory B cells in the patient, plasmablast numbers were comparable to controls (Fig. 3J) (Supp. Fig. 1A), perhaps explaining the patient's normal serum immunoglobulin levels. Expanding our naïve B cell analyses further, we observed markedly elevated IgD expression (Fig. 3K) (Supp. Fig. 1B) and generally comparable to control IgM expression (Fig. 3K) (Supp. Fig. 1C) in patient naïve B cells. These IgDhi naïve B cells were characterized by elevated expression of the cell proliferation marker Ki67 (Fig. 3L, **3M**), but significantly reduced TNF- $\alpha$  expression (**Fig. 3N, 3O**) which was consistent with the scRNA-Seg data. Given the striking B cell differentiation defect in the patient, we next asked whether this was intrinsic or extrinsic to B cells. We isolated naïve B cells from the patient and controls and quantified the frequency of class-switched memory B cells and plasmablasts before and after treatment with an in vitro B cell activation and expansion cocktail. We demonstrated intact differentiation of both memory B cells (Fig. 3P) (Supp. Fig. 1D) and plasmablasts (Fig. 3P, 3Q), suggesting that the differentiation defect is likely to be extrinsic to B cells. NFAT1 deficient CD8<sup>+</sup> T cells show impaired polyfunctionality Since both NFAT1 deficiency and calcineurin inhibitor treatment are known to suppress CD8<sup>+</sup> T cell effector function<sup>58, 59</sup> and suppressed CD8<sup>+</sup> T cells can create conditions that favour lymphomagenesis<sup>60</sup>, we next analyzed CD8<sup>+</sup> T cell differentiation and function by scRNA-Seq and flow cytometry. DE analysis of patient memory CD8<sup>+</sup> T cells revealed a mixed effector function defect, including decreased transcript abundance of TNF, IFNG, and FASLG, but increased GZMH, GNLY, and PFN1 (Fig. 4A, 4B). Flow cytometric analysis of CD8<sup>+</sup> T cell subsets revealed no differences in patient naïve and

539 memory populations when compared to controls (Fig. 4C, 4D). However, whereas control CD8 populations expressed easily detectable levels of NFAT1 protein, patient 540 541 CD8 populations were NFAT1-deficient (Fig. 4E). In line with the abnormal effector marker profile in scRNA-Seq, patient CD8<sup>+</sup> memory T cells showed significantly 542 543 impaired expression of TNF-α and IFN-y expression in response to stimulation (Fig. 4F-**4H**). In contrast, IL-2 expression was intact in both patient naïve and memory CD8<sup>+</sup> T 544 545 cells (Supp. Fig. 2A-D). Patient CD8<sup>+</sup> memory T cells also exhibited abnormal expression of activation markers, including comparable to control expression of CD40L 546 (Supp. Fig. 2E-F) and PD-1 (Fig. 4I) (Supp. Fig. 2H), but elevated CD69 (Fig. 4I) 547 (**Supp. Fig. 2G**). These findings indicate a pleiotropic function for NFAT1 in human 548 CD8<sup>+</sup> T cells. 549 550 NFAT1 deficiency causes an accumulation of non-functional memory CD4<sup>+</sup> T cells 551 552 The role of NFAT1 in CD4 cell functionality and differentiation is well characterized in mouse studies<sup>14</sup>. We sought to see if this held true in human complete NFAT1 553 deficiency, scRNA-Seg revealed a marked increase in the memory CD4<sup>+</sup>T cell 554 compartment (Fig. 3A). We conducted DE analysis on these cells and found 555 556 significantly impaired expression of many makers for T helper function (i.e. TNF and CD40LG) and cell proliferation (i.e. MYC) (Fig. 5A, 5B). In addition, we observed 557 increased expression of other activation/exhaustion-related genes such as TIGIT, 558 S100A10 and TNFRSF4 (Fig. 5A, 5B). Interestingly, many regulatory components of 559 the NF-kB pathway (NFKBIZ, NFKBIA, REL) and AP-1 pathway (FOS and JUN) 560 showed impaired expression in NFAT1 deficient cells (Fig. 5A, 5B), highlighting the 561 broad defects associated with human NFAT1 deficiency. 562 We next examined the impact of NFAT1 deficiency on CD4<sup>+</sup> T cell differentiation by flow 563 cytometry. Confirming our scRNA-Seq data, the patient possessed decreased naïve 564 CD4<sup>+</sup> T cells with a concurrent increase in CD4<sup>+</sup> central memory T cells (**Fig. 5C, 5D,** 565 Supp. Table 2) and both these subsets had undetectable levels of NFAT1 protein, in 566 contrast to controls (Fig. 5E). Within the memory CD4<sup>+</sup> T cell compartment, the patient 567 had significantly decreased T<sub>H</sub>1, T<sub>H</sub>2, T<sub>H</sub>17 and T<sub>FH</sub> cells as measured by cytokine (i.e. 568

- IFN-γ, IL-4, IL-17A and IL-21) production (Fig. 5F-5K). Furthermore, classical NFAT1
- targets IL-2 and TNF-α<sup>7</sup>, were significantly reduced in patient memory CD4<sup>+</sup> T cells
- (Fig. 5L, 5M). In contrast, naïve CD4<sup>+</sup> T cells did not exhibit any significant differences
- in the expression of these same cytokines (**Supp. Fig. 3A-3I**).

## Human NFAT1 deficiency does not cause any overt defects in Tregs

- 575 Since NFAT1 was shown to be critical for controlling Treg suppressive function in
- mouse models<sup>61</sup>, we studied whether Treg development and/or function was affected in
- NFAT1 deficiency. Surprisingly, we found normal frequencies of Tregs and their naïve
- and activated subsets (Supp. Fig. 5A-5C). From a functional standpoint, activated
- patient Tregs showed significantly reduced TNF- $\alpha$  (Supp. Fig. 5D-5E), but normal IFN- $\gamma$
- (Supp. Fig. 5D-5E) and IL-2 (Supp. Fig. 5G-5H) expression. Similarly, Treg markers of
- stability and activation were largely normal, including FOXP3, Helios, CD25, CD69,
- 582 CTLA4, and ICOS (**Supp. Fig. 5I-5N**), except for PD-1, which was significantly elevated
- 583 **(Supp. Fig. 50)**.

573

574

584

585

#### NFAT1 deficiency impairs T<sub>FH</sub> function

- Given the impaired production of a variety of T cell cytokines (Fig. 5F-5N) by CD4<sup>+</sup>
- memory T cells, we asked whether the expression of activation markers and critical T
- cell coreceptors by this T cell population is affected by NFAT1 deficiency. Here we
- found significantly increased CD69, PD-1, and ICOS, but decreased CD25 and CD40L
- after P/I treatment (Fig. 6A) (Supp. Fig. 3P-3T). A similar profile was observed in naïve
- 591 CD4<sup>+</sup> T cells (**Supp. Fig. 3K-5O**).
- Reduced CD4<sup>+</sup> memory T cell activation marker expression and cytokine secretion
- 593 paired with an extrinsic B cell differentiation defect prompted us to assess frequency
- and function of circulating T<sub>FH</sub> cells in the patient (**Supp. Fig. 4A**). Confirming cytokine
- staining (**Fig. 5F-5K**), T<sub>FH</sub> numbers were comparable to controls (**Fig. 6B, 6C**). Despite
- 596 this, the expression of CD40L and IL-21, both important for B cell activation and

differentiation<sup>62</sup>, was markedly impaired (**Fig. 6D-6F**). Importantly, these defects were reversed when we transduced patient CD4<sup>+</sup> T cells with WT *NFATC2*, which restored CD40L and TNF- $\alpha$  expression to a level that was comparable to healthy controls (**Fig. 6G-6I**).

#### DISCUSSION

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

Here we present a comprehensive clinical, immunological, biochemical, and transcriptional workup of the first reported case of human complete NFAT1 deficiency in a young man with a clinical triad of: progressive joint contractures, osteochondromas, and B cell malignancy. Based on our study, patients should be worked up for possible NFAT1 deficiency if they present with this triad of features. Although the full phenotype of human NFAT1 deficiency will only be appreciated when more affected individuals are identified, other clinical flags include: i) impaired B cell development (increased naïve, decreased memory); ii) normal CD8<sup>+</sup> T cell development but impaired TNF- $\alpha$  and IFN- $\gamma$ production and elevated CD69 expression; and iii) increased CD4<sup>+</sup> memory proportions with reduced T<sub>H</sub> subsets and cytokine secretion, and increased CD69, PD-1, ICOS expression. Notably, haploinsufficiency (at least with this particular null variant) was not observed as all heterozygous family members were healthy and unaffected. Studying *Nfatc2*-/- mice has been extremely informative in defining the physiological functions of NFAT1. This includes regulation of chondrogenesis 18 and bone development<sup>19, 63</sup>, maintenance of steady state hematopoiesis<sup>63</sup>, suppression and regulation of T cells<sup>64, 65</sup>, and B cell lymphomagenesis<sup>34</sup>. Reassuringly, human NFAT1 deficiency recapitulates a variety of the features seen in the knockout mice (Table 2). The joint contractures and progressive difficulty in ambulation observed in our NFAT1deficient patient were accurately predicted by Nfatc2<sup>-/-</sup> mice, as was the with excess differentiation, proliferation, and endochondral ossification affecting cartilage cells<sup>18</sup>. The pro-growth, pro-survival, and proinflammatory phenotype of patient chondrocytes (Fig. 2) suggests that human NFAT1 serves as a repressor of cartilage cell growth and differentiation. Future work will focus on studying how osteopenia arises in the context of human NFAT1 deficiency and the contributions of different mesenchymal cells to the patient's musculoskeletal phenotype. Interestingly, bone fractures and osteopenia have also been observed in *Nfatc2*-/- or tacrolimus-treated mice<sup>19</sup>, and organ transplant recipients on immunosuppressive regimens that include glucocorticoids and tacrolimus<sup>66</sup>, further strengthening the link to NFAT1 function. In light of these observations, it is important to consider other findings in *Nfatc2*-/- mice, notably the

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

development of chondrosarcomas<sup>18</sup> and susceptibility to osteoarthiritis<sup>20</sup>, as additional patients with NFAT1 deficiency are identified. One of the most significant phenotypes in our patient was the development of a rare mature B cell lymphoma characterized by large CD20<sup>+</sup>CD30<sup>+</sup>CD15<sup>-</sup>BCL6<sup>+</sup> cells (Fig. **1C**). Intriguingly, an increased incidence of anaplastic and/or plasmablastic plasmacytomas –also rare– was also observed with aging *Nfatc2*-/- mice<sup>34</sup>. Abrogation of NFAT1 function in B cells may confer an intrinsic pro-survival transcriptional program. NFAT1 is critical for repressing cell cycle progression through cyclin E (CCNE2)<sup>67</sup> and our findings extend this understanding to suggest that JNK signaling (via DUSP4<sup>68</sup>) and AKT signaling (via *PIK3AP1*<sup>55</sup>) (**Fig. 3B, 3C**), might contribute to dysregulated B cell proliferation in the context of NFAT1 deficiency. In parallel, the CD4<sup>+</sup> T cells of the NFAT1-deficient patient expressed high levels of the inhibitory checkpoint marker, PD-1 (Fig. 6A), which has frequently been associated with B cell lymphomas<sup>69, 70</sup>. This could inhibit effective anti-tumour effector functions in the patient. This is likely further exacerbated by the markedly reduced production of effector cytokines (TNF-α, IFN-y) in patient's CD4<sup>+</sup> and CD8<sup>+</sup> T cells (**Fig. 4-5**). Together these data indicate that ongoing clinical tumor surveillance, and a heightened awareness of tumor risk, will be an important aspect of the long-term care of patients with NFAT1 deficiency. Studying complete human germline NFAT1 deficiency can provide new insights into the use of calcineurin inhibitors and improves our understanding of the consequences of long-term NFAT1 inhibition by calcineurin inhibitors (**Table 2**). Patients undergoing solid organ or allogeneic hematopoietic stem cell transplantation are frequently treated with an immunosuppressive regimen including a calcineurin inhibitor for extended periods of time. This can lead to a rare complication called post-transplant lymphoproliferative disorder (PTLD). Most PTLD's are a B cell proliferative disorder believed to be due to impaired CD8<sup>+</sup> T cell function and EBV infection<sup>71,72</sup>. Our findings complement this understanding since NFAT1-deficient CD8<sup>+</sup> T cells express significantly reduced cytotoxic mediators such as FASLG and IFNG (Fig. 4B, 4H). Consistent with NFAT1dependent regulation of the transcription factor Egr3 being critical for FasL induction<sup>73</sup>, we found that both EGR3 and FASLG were downregulated in CD4<sup>+</sup> and CD8<sup>+</sup> patient

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

memory T cells (Fig. 4-5). Future work should focus on the role of NFAT1 in intrinsic B cell proliferation and CD4<sup>+</sup> T cell exhaustion and the role of these factors in the pathophysiology of PTLD. Mechanistically, human NFAT1 deficiency has revealed the remarkable pleiotropic and cell-type specific functions of NFAT1. Our study supports previous work that ascribed both oncogenic and tumor suppressor roles to NFAT1, depending on the cell type<sup>24</sup>. Informed by this patient, NFAT1 serves as a tumor suppressor in chondrocytes and B cells. This work also clarifies the role of human NFAT1 in B cell class-switching. Specifically, the B cell differentiation block is likely attributable to impaired T cell help. Previous studies demonstrated that both NFAT1 and NFAT2 are important for T<sub>FH</sub> differentiation<sup>15</sup>. However, this NFAT1-deficient patient demonstrates that human NFAT1 is likely dispensable for T<sub>FH</sub> differentiation but is critical for T<sub>FH</sub> activation and function (Fig. 6B-I). Similarly, NFAT1 is essential for T<sub>H</sub> cell differentiation and cytokine production (Fig. 5F-5N). One possible explanation for impaired CD4<sup>+</sup> memory function could be that they are exhausted. This is supported by high PD-1 (Fig. 6A), and TIGIT (Fig. 5A-5B) expression<sup>74</sup>. Accumulation of memory T cells<sup>34, 75</sup>, along with hyperresponsiveness has been documented in T cells of *Nfatc2*<sup>-/-</sup> mice<sup>64, 65, 75, 76</sup>. We observed suppressed cytokine signaling in the patient memory CD4<sup>+</sup> and CD8<sup>+</sup> cells. However, patient naïve CD4<sup>+</sup> T cells do display signatures of activation, with higher PD-1 and CD69 (Supp. Fig. 2J – **2T**), as well as higher expression of T cell activation markers CXCR3<sup>11</sup>, ITGA4 (an a subunit of integrin receptors), and IL2RB (CD122) (Supp. Table 3), a cytokine receptor recently found to be involved in homeostatic proliferation of naïve CD4<sup>+</sup> T cells<sup>78</sup>. Higher activation status in naïve T cells might explain the age-associated accumulation of memory T cells observed in knock-out mice<sup>34</sup> and the NFAT1-deficient patient. Given the significant T and B cell dysregulation identified in this NFAT1-deficient patient and the absence of classical features for immunodeficiency (recurrent/severe/unusual infections), we propose to classify human NFAT1 deficiency as a primary immune regulatory disorder<sup>79</sup>. Studying this first reported patient has given us unique insight into the role of NFAT1 in the human musculoskeletal and immune systems. Our findings

corroborate decades of *Nfatc2*--- murine studies, while also providing a mechanistic understanding of human NFAT1 deficiency in different cell types. Beyond individual patients, this study also informs the clinical implementation of calcineurin inhibitors and highlights potential adverse consequences of long-term use.

# Table 1: Major Clinical Features. Patient clinical features organized by

musculoskeletal or immunological/hematological abnormalities.

Musculoskeletal	Immunological/Hematological
Contractures of upper limb joints, hips, knees, ankles	B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and cHL
Mobility issues: stiff gait, decreased stride length, toe walking	Widespread lymphadenopathy: abdominal, inguinal, hepatic, splenic, paratracheal, subcarinal, bone. No bone marrow involvement.
Decreased arm swing and knee range of motion. Anterior pelvic tilt with adduction of thighs	Lymph node tissue demonstrates malignant, large, mono- or binucleated cells within a benign background inflammatory cell infiltrate composed of small lymphocytes, eosinophils, histiocytes, and neutrophils
Ill-defined sclerotic bands present in the metaphyses of both the femoral tibia and fibula	Lymph node: effaced/abnormal architecture, large atypical CD79a <sup>+</sup> CD30 <sup>+</sup> CD20 <sup>+</sup> CD15 <sup>-</sup> PAX5 <sup>+</sup> B cells, positive BCL6 rearrangement, negative BCL2 rearrangement
Presence of multiple small pedunculated osteochondromas	
Developed severe spinal cord stenosis at level C3 C4, requiring posterior cervical decompression and fusion	
Bone Density Scan (DEXA): <u>Lumbar spine L1-4</u> : 0.739 (g/cm²); Z-Score for chronologic age: -1.4; Z-score corrected for height: +0.2 <u>Total left hip</u> : 0.865 (g/cm²); Z-Score for chronological age 1.0; Z-score corrected for height: +0.2 <u>Total body</u> : 0.888 (g/cm²); Z-Score for chronologic age: -1.9; Z-score corrected for height: -0.4	
No evidence of muscle necrosis or regeneration, no increased endomysia fibrous tissue, no inflammation, no atypical cells	

# Table 2: Comparison of human NFAT1 deficiency, Nfatc2-/- mice, and patients on calcineurin inhibitors.

	NFAT1 deficient patient	<i>Nfatc2</i> <sup>-/-</sup> KO mice	Use of calcineurin inhibitors
Skeletal abnormalities and cartilage/ chondrocyte	Joint contractures, difficulty in ambulation. decreased range of motion in joints.	Joint contractures, difficulty in ambulation. decreased range of motion in joints <sup>18</sup> .	
defects	Increased cell cycling, resistance to apoptosis in osteochondroma chondrocytes	Invasive cartilage cells <i>in</i> vivo and contact-induced growth inhibition in vitro, Chondrosarcoma <sup>18</sup> .	Proliferation of chondrocytes from articular cartilage <sup>80</sup> .
	Increased MMP9 and increased IL6/IL-6-STAT3 pathway in patient chondrocytes	Susceptible to osteoarthritis, increased catabolic and decreased anabolic activity in articular cartilage, increased <i>IL6</i> <sup>20</sup> .	
	Low total body bone mineral density with vertebral compression fractures	Decreased bone volume <sup>19</sup> .	Posttransplant osteoporosis in organ recipients <sup>66</sup> , reduced bone mass and osteoporosis in FK506-treated mice in mice <sup>19</sup> and rats <sup>81</sup> .
B cell lymphoma and malignancies	Effaced lymph node architecture, showing B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and cHL	Effaced lymph node architecture, increased incidence of B cell malignancies, features of anaplastic and/or plasmablastic plasmacytomas, and none in <i>Nfatc2</i> <sup>+</sup> / <sup>34</sup> .	Post-transplant lymphoproliferative disorder (PTLD) mostly in EBV <sup>+</sup> B cells <sup>82, 83</sup> , antiapoptotic effects in Burkitt's lymphoma cell line <sup>84</sup> , increased incidence of lymphoma with topical calcineurin inhibitors <sup>85, 86</sup> .
CD4 <sup>+</sup> T cells impairments	Higher activated (CD69 <sup>+</sup> ) T cells, accumulation of CD4 <sup>+</sup> central memory that exhibit high PD-1 expression	Age-related increase in accumulation of activated CD69 <sup>+</sup> T cells and memory T cells in secondary lymphoid organs <sup>34</sup> .	Increase in CD4 <sup>+</sup> T cell exhaustion post-kidney and post-liver transplants but not CD8 <sup>+87, 88, 89</sup> .
T follicular helper cell impairment	T <sub>FH</sub> cells activation is impaired and there is a lack of B cell class switching.	Nfatc1/Nfatc2 double knockout mice: impaired T <sub>FH</sub> differentiation and function, impaired GC formation <sup>15</sup> .	Decreased T <sub>FH</sub> numbers and function, low T <sub>FH</sub> - mediated B cell differentiation in transplant patients <sup>90, 91</sup> .

#### REFERENCES

711

713

716

719

722

725

728

731

734

737

740

743

746

- 712 1. Vig, M. & Kinet, J.P. Calcium signaling in immune cells. *Nat Immunol* **10**, 21-27 (2009).
- 714 2. Vaeth, M., Kahlfuss, S. & Feske, S. CRAC Channels and Calcium Signaling in T Cell-Mediated Immunity. *Trends Immunol* **41**, 878-901 (2020).
- 717 3. Feske, S. Calcium signalling in lymphocyte activation and disease. *Nat Rev Immunol* **7**, 690-702 (2007).
- 720 4. Vaeth, M. & Feske, S. NFAT control of immune function: New Frontiers for an Abiding Trooper. 721 *F1000Res* **7**, 260 (2018).
- 723 5. Macian, F. NFAT proteins: key regulators of T-cell development and function. *Nat Rev Immunol* 5, 472-484 (2005).
- Loh, C. *et al.* Calcineurin binds the transcription factor NFAT1 and reversibly regulates its activity. *J Biol Chem* **271**, 10884-10891 (1996).
- 729 7. Luo, C. *et al.* Recombinant NFAT1 (NFATp) is regulated by calcineurin in T cells and mediates transcription of several cytokine genes. *Mol Cell Biol* **16**, 3955-3966 (1996).
- How the first state of the transcription factor NFAT1 that controls nuclear import. *Proc Natl Acad Sci U S A* **93**, 8907-8912 (1996).
- 735 9. Shaw, K.T. *et al.* Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. *Proc Natl Acad Sci U S A* **92**, 11205-11209 (1995).
- 738 10. Clipstone, N.A. & Crabtree, G.R. Identification of calcineurin as a key signalling enzyme in T-739 lymphocyte activation. *Nature* **357**, 695-697 (1992).
- 741 11. Rao, A., Luo, C. & Hogan, P.G. Transcription factors of the NFAT family: regulation and function.
  742 Annu Rev Immunol 15, 707-747 (1997).
- The Shibasaki, F., Price, E.R., Milan, D. & McKeon, F. Role of kinases and the phosphatase calcineurin in the nuclear shuttling of transcription factor NF-AT4. *Nature* **382**, 370-373 (1996).
- 747 13. Shaw, J.P. *et al.* Identification of a putative regulator of early T cell activation genes. *Science* **241**, 202-205 (1988).

750 14. Hermann-Kleiter, N. & Baier, G. NFAT pulls the strings during CD4+ T helper cell effector functions. *Blood* **115**, 2989-2997 (2010).

752

755

758

761

764

767

770

774

777

780

784

- 753 15. Martinez, G.J. *et al.* Cutting Edge: NFAT Transcription Factors Promote the Generation of Follicular Helper T Cells in Response to Acute Viral Infection. *J Immunol* **196**, 2015-2019 (2016).
- 756 16. Peng, S.L., Gerth, A.J., Ranger, A.M. & Glimcher, L.H. NFATc1 and NFATc2 together control both T and B cell activation and differentiation. *Immunity* **14**, 13-20 (2001).
- 759 17. Zanoni, I. *et al.* CD14 regulates the dendritic cell life cycle after LPS exposure through NFAT activation. *Nature* **460**, 264-268 (2009).
- 762 18. Ranger, A.M. *et al.* The nuclear factor of activated T cells (NFAT) transcription factor NFATp (NFATc2) is a repressor of chondrogenesis. *J Exp Med* **191**, 9-22 (2000).
- 765 19. Koga, T. *et al.* NFAT and Osterix cooperatively regulate bone formation. *Nat Med* **11**, 880-885 (2005).
- 768 20. Wang, J. *et al.* Transcription factor Nfat1 deficiency causes osteoarthritis through dysfunction of adult articular chondrocytes. *J Pathol* **219**, 163-172 (2009).
- 771 21. Ho, I.C., Kim, J.H., Rooney, J.W., Spiegelman, B.M. & Glimcher, L.H. A potential role for the 772 nuclear factor of activated T cells family of transcriptional regulatory proteins in adipogenesis. 773 *Proc Natl Acad Sci U S A* **95**, 15537-15541 (1998).
- 775 22. Bourajjaj, M. *et al.* NFATc2 is a necessary mediator of calcineurin-dependent cardiac hypertrophy and heart failure. *J Biol Chem* **283**, 22295-22303 (2008).
- 778 23. Jauliac, S. *et al.* The role of NFAT transcription factors in integrin-mediated carcinoma invasion.
  779 *Nat Cell Biol* **4**, 540-544 (2002).
- 781 24. Mognol, G.P., Carneiro, F.R., Robbs, B.K., Faget, D.V. & Viola, J.P. Cell cycle and apoptosis 782 regulation by NFAT transcription factors: new roles for an old player. *Cell Death Dis* **7**, e2199 783 (2016).
- Casolaro, V. *et al.* Inhibition of NF-AT-dependent transcription by NF-kappa B: implications for differential gene expression in T helper cell subsets. *Proc Natl Acad Sci U S A* **92**, 11623-11627 (1995).
- 789 26. Liu, J. *et al.* Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. *Cell* **66**, 807-815 (1991).

791		
792	27.	First, M.R. Tacrolimus based immunosuppression. <i>J Nephrol</i> <b>17 Suppl 8</b> , S25-31 (2004).
793 794 795	28.	Azzi, J.R., Sayegh, M.H. & Mallat, S.G. Calcineurin inhibitors: 40 years later, can't live without. <i>J Immunol</i> <b>191</b> , 5785-5791 (2013).
796 797 798	29.	Cury Martins, J. et al. Topical tacrolimus for atopic dermatitis. <i>Cochrane Database Syst Rev</i> , CD009864 (2015).
799 800	30.	Safarini, O.A. & Patel, J. Calcineurin Inhibitors. <i>StatPearls</i> : Treasure Island (FL), 2021.
801 802 803	31.	Lee, M. & Park, J. Regulation of NFAT activation: a potential therapeutic target for immunosuppression. <i>Mol Cells</i> <b>22</b> , 1-7 (2006).
804 805 806	32.	van Kuilenburg, A.B.P. <i>et al.</i> Glutaminase Deficiency Caused by Short Tandem Repeat Expansion in GLS. <i>N Engl J Med</i> <b>380</b> , 1433-1441 (2019).
807 808 809	33.	Tarailo-Graovac, M. <i>et al.</i> Exome Sequencing and the Management of Neurometabolic Disorders. <i>N Engl J Med</i> <b>374</b> , 2246-2255 (2016).
810 811 812	34.	May, S.L. <i>et al.</i> Nfatc2 and Tob1 have non-overlapping function in T cell negative regulation and tumorigenesis. <i>PLoS One</i> <b>9</b> , e100629 (2014).
813 814 815	35.	Lu, H.Y. <i>et al.</i> Mechanistic understanding of the combined immunodeficiency in complete human CARD11 deficiency. <i>J Allergy Clin Immunol</i> (2021).
816 817 818	36.	Lu, H.Y. <i>et al.</i> The importance of functional validation after next-generation sequencing: evaluation of a novel CARD11 variant. <i>Pediatr Allergy Immunol</i> <b>29</b> , 663-668 (2018).
819 820 821	37.	Fung, S.Y. <i>et al.</i> MALT1-Dependent Cleavage of HOIL1 Modulates Canonical NF-kappaB Signaling and Inflammatory Responsiveness. <i>Front Immunol</i> <b>12</b> , 749794 (2021).
822 823 824	38.	Kutner, R.H., Zhang, X.Y. & Reiser, J. Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. <i>Nat Protoc</i> <b>4</b> , 495-505 (2009).
825 826 827	39.	Jia, A. et al. Clinical IRAK4 deficiency caused by homozygosity for the novel IRAK4 (c.1049delG, p.Gly350Glufs*15) variant. Cold Spring Harb Mol Case Stud 6 (2020).
828 829 830	40.	Carson, R.T. & Vignali, D.A. Simultaneous quantitation of 15 cytokines using a multiplexed flow cytometric assay. <i>J Immunol Methods</i> <b>227</b> , 41-52 (1999).

831 832 41. Livak, K.J. & Schmittgen, T.D. Analysis of relative gene expression data using real-time 833 quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-408 (2001). 834 835 42. Chen, Y., Lun, A.T. & Smyth, G.K. From reads to genes to pathways: differential expression 836 analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood pipeline. 837 F1000Res 5, 1438 (2016). 838 839 43. Ritchie, M.E. et al. limma powers differential expression analyses for RNA-sequencing and 840 microarray studies. Nucleic Acids Res 43, e47 (2015). 841 842 44. Kulpa, D.A. et al. Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency 843 Reversal in CD4(+) T Cells. J Virol 93 (2019). 844 845 45. Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic 846 data across different conditions, technologies, and species. Nat Biotechnol 36, 411-420 (2018). 847 848 46. Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional 849 profibrotic macrophage. Nat Immunol 20, 163-172 (2019). 850 851 47. Novershtern, N. et al. Densely interconnected transcriptional circuits control cell states in 852 human hematopoiesis. Cell **144**, 296-309 (2011). 853 854 48. Hafemeister, C. & Satija, R. Normalization and variance stabilization of single-cell RNA-seq data 855 using regularized negative binomial regression. Genome Biol 20, 296 (2019). 856 857 49. Robinson, M.D. & Smyth, G.K. Moderated statistical tests for assessing differences in tag 858 abundance. Bioinformatics 23, 2881-2887 (2007). 859 860 50. Burrage, P.S., Mix, K.S. & Brinckerhoff, C.E. Matrix metalloproteinases: role in arthritis. Front 861 Biosci 11, 529-543 (2006). 862 863 51. Nguyen, L., Papenhausen, P. & Shao, H. The Role of c-MYC in B-Cell Lymphomas: Diagnostic and 864 Molecular Aspects. Genes (Basel) 8 (2017). 865 866 52. McGettrick, A.F. & O'Neill, L.A.J. The Role of HIF in Immunity and Inflammation. Cell Metab 32, 867 524-536 (2020). 868 869 53. Zhu, F., Wang, K.B. & Rui, L. STAT3 Activation and Oncogenesis in Lymphoma. Cancers (Basel) 12 870 (2019).


871 872 54. Zhang, Y. et al. Tumor necrosis factor-alpha induced protein 8 polymorphism and risk of non-873 Hodgkin's lymphoma in a Chinese population: a case-control study. PLoS One 7, e37846 (2012). 874 875 55. Corso, J. et al. Elucidation of tonic and activated B-cell receptor signaling in Burkitt's lymphoma 876 provides insights into regulation of cell survival. Proc Natl Acad Sci U S A 113, 5688-5693 (2016). 877 878 56. Jasenosky, L.D. et al. Identification of a Distal Locus Enhancer Element That Controls Cell Type-879 Specific TNF and LTA Gene Expression in Human T Cells. J Immunol 205, 2479-2488 (2020). 880 881 57. Kuprash, D.V. et al. Cyclosporin A blocks the expression of lymphotoxin alpha, but not 882 lymphotoxin beta, in human peripheral blood mononuclear cells. Blood 100, 1721-1727 (2002). 883 884 58. Xu, T., Keller, A. & Martinez, G.J. NFAT1 and NFAT2 Differentially Regulate CTL Differentiation 885 Upon Acute Viral Infection. Front Immunol 10, 184 (2019). 886 887 59. Vafadari, R., Kraaijeveld, R., Weimar, W. & Baan, C.C. Tacrolimus inhibits NF-kappaB activation in 888 peripheral human T cells. PLoS One 8, e60784 (2013). 889 890 60. Nassef Kadry Naguib Roufaiel, M., Wells, J.W. & Steptoe, R.J. Impaired T-Cell Function in B-Cell 891 Lymphoma: A Direct Consequence of Events at the Immunological Synapse? Front Immunol 6, 892 258 (2015). 893 894 61. Shin, D.S. et al. Regulatory T cells suppress CD4+ T cells through NFAT-dependent transcriptional 895 mechanisms. EMBO Rep 15, 991-999 (2014). 896 897 62. Ding, B.B., Bi, E., Chen, H., Yu, J.J. & Ye, B.H. IL-21 and CD40L synergistically promote plasma cell 898 differentiation through upregulation of Blimp-1 in human B cells. J Immunol 190, 1827-1836 899 (2013).900 901 63. Bauer, W. et al. Osteomyelosclerosis, anemia and extramedullary hematopoiesis in mice lacking 902 the transcription factor NFATc2. Haematologica 96, 1580-1588 (2011). 903 904 64. Xanthoudakis, S. et al. An enhanced immune response in mice lacking the transcription factor 905 NFAT1. Science 272, 892-895 (1996). 906 Hodge, M.R. et al. Hyperproliferation and dysregulation of IL-4 expression in NF-ATp-deficient 907 65. 908 mice. Immunity 4, 397-405 (1996). 909 910 66. Yu, T.M. et al. Osteoporosis and fractures after solid organ transplantation: a nationwide

population-based cohort study. Mayo Clin Proc 89, 888-895 (2014).

912 913 67. Teixeira, L.K. et al. NFAT1 transcription factor regulates cell cycle progression and cyclin E 914 expression in B lymphocytes. Cell Cycle 15, 2346-2359 (2016). 915 916 68. Schmid, C.A. et al. DUSP4 deficiency caused by promoter hypermethylation drives JNK signaling 917 and tumor cell survival in diffuse large B cell lymphoma. J Exp Med 212, 775-792 (2015). 918 919 69. Xu-Monette, Z.Y., Zhou, J. & Young, K.H. PD-1 expression and clinical PD-1 blockade in B-cell 920 lymphomas. Blood 131, 68-83 (2018). 921 922 70. Rosales, Y.M.Z. et al. Use of checkpoint inhibitors in gray zone lymphoma. Hematol Oncol Stem. 923 Cell Ther (2020). 924 925 Al-Mansour, Z., Nelson, B.P. & Evens, A.M. Post-transplant lymphoproliferative disease (PTLD): 71. 926 risk factors, diagnosis, and current treatment strategies. Curr Hematol Maliq Rep 8, 173-183 927 (2013).928 929 72. Singavi, A.K., Harrington, A.M. & Fenske, T.S. Post-transplant lymphoproliferative disorders. 930 Cancer Treat Res **165**, 305-327 (2015). 931 932 73. Rengarajan, J. et al. Sequential involvement of NFAT and Egr transcription factors in FasL 933 regulation. Immunity 12, 293-300 (2000). 934 935 74. Miggelbrink, A.M. et al. CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer? 936 Clin Cancer Res 27, 5742-5752 (2021). 937 938 75. Karwot, R. et al. Protective role of nuclear factor of activated T cells 2 in CD8+ long-lived 939 memory T cells in an allergy model. J Allergy Clin Immunol 121, 992-999 e996 (2008). 940 941 76. Kwon, H.K. et al. Transcription factor NFAT1 controls allergic contact hypersensitivity through 942 regulation of activation induced cell death program. Sci Rep 6, 19453 (2016). 943 944 77. Kuo, P.T. et al. The Role of CXCR3 and Its Chemokine Ligands in Skin Disease and Cancer. Front 945 Med (Lausanne) 5, 271 (2018). 946 947 78. Keller, H.R. et al. The Abundance and Availability of Cytokine Receptor IL-2Rbeta (CD122) 948 Constrain the Lymphopenia-Induced Homeostatic Proliferation of Naive CD4 T Cells. J Immunol 949 **204**, 3227-3235 (2020). 950 951 79. Chan, A.Y. & Torgerson, T.R. Primary immune regulatory disorders: a growing universe of 952 immune dysregulation. Curr Opin Allergy Clin Immunol 20, 582-590 (2020).

953 954 80. Kang, S.W., Kim, J. & Shin, D.Y. Inhibition of senescence and promotion of the proliferation of 955 chondrocytes from articular cartilage by CsA and FK506 involves inhibition of p38MAPK. Mech 956 Ageing Dev 153, 7-13 (2016). 957 958 81. Kirino, S. et al. Regulation of bone metabolism in immunosuppressant (FK506)-treated rats. J 959 Bone Miner Metab 22, 554-560 (2004). 960 961 82. Caduff, N. et al. Immunosuppressive FK506 treatment leads to more frequent EBV-associated 962 lymphoproliferative disease in humanized mice. PLoS Pathog 16, e1008477 (2020). 963 964 83. Taylor, A.L., Marcus, R. & Bradley, J.A. Post-transplant lymphoproliferative disorders (PTLD) after 965 solid organ transplantation. Crit Rev Oncol Hematol 56, 155-167 (2005). 966 967 84. Kondo, E. et al. NF-ATc2 induces apoptosis in Burkitt's lymphoma cells through signaling via the 968 B cell antigen receptor. Eur J Immunol 33, 1-11 (2003). 969 970 85. Lam, M., Zhu, J.W., Tadrous, M. & Drucker, A.M. Association Between Topical Calcineurin 971 Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma: 972 A Systematic Review and Meta-analysis. JAMA Dermatol 157, 549-558 (2021). 973 974 86. Wu, P.C., Huang, I.H., Liu, C.W. & Huang, Y.C. Topical calcineurin inhibitors and risk of 975 lymphoma: a systematic review and meta-analysis. J Dtsch Dermatol Ges 19, 1265-1269 (2021). 976 977 87. Angeletti, A., Cantarelli, C., Riella, L.V., Fribourg, M. & Cravedi, P. T Cell Exhaustion in Organ 978 Transplantation. Transplantation (2021). 979 980 88. Fribourg, M. et al. T-cell exhaustion correlates with improved outcomes in kidney transplant 981 recipients. Kidney Int 96, 436-449 (2019). 982 983 89. Li, J. et al. Regulatory effect of FK506 on CD152 and PD-1 in the liver allorecipients. Transplant 984 Proc 40, 1495-1497 (2008). 985 986 90. Zhang, K. et al. A pilot study on the characteristics of circulating T follicular helper cells in liver 987 transplant recipients. Transpl Immunol 47, 32-36 (2018). 988 989 91. Wallin, E.F., Hill, D.L., Linterman, M.A. & Wood, K.J. The Calcineurin Inhibitor Tacrolimus Specifically Suppresses Human T Follicular Helper Cells. Front Immunol 9, 1184 (2018). 990 991

994 Figures:



997

998

999

1000

1001

1002

1003

1004

1005

1006

1007

1008

1009

1010

1011


1012

1013

1014

1015

Fig. 1. Clinical phenotype of a patient with NFAT1 deficiency, joint contractures, and B cell malignancy. A) X-ray demonstrating extent to which knees could be straightened documenting the fixed flexion deformity. B) Osteochondroma (indicated by the arrow) on the anterior aspect of the right proximal fibula. **C)** Hematoxylin and eosin (H&E) stain, and CD20, CD21, CD30, BCL2, and BCL6 immunostain of a patient lymph node biopsy. Scale bar for H&E, CD20, CD30, BCL6, and BCL2 is 50µm and for CD21 is 3mm. **D)** Family pedigree. Half-filled symbols=heterozygous unaffected individuals. filled symbols=homozygous affected individual, arrow=proband, question marks=ungenotyped. E) Sanger sequencing of DNA extracted from whole blood of the patient, family members, and a healthy control. Site of four base pair deletion is indicated. F) Schematic illustrating the protein domains of NFAT1. Location of variant shown in red. Affected region was aligned to other species. Asterisks indicate full conservation. G) Schematic illustrating ionomycin-induced activation of calcineurin and NFAT1. **H)** NFATC2 transcript abundance relative to  $\beta$ -actin (ACTB) in the patient (II-1), a heterozygous control (II-2), and a healthy control (HC) determined by gPCR. Red circles=II-1, blue circles=II-2, green circles=HC. \*\* p<0.01, \*\*\*\*p<0.0001. One-way ANOVA and Tukey's post-hoc test. I) Immunoblot of patient (II-1), heterozygous control (II-2), and control-derived LCLs using an N-terminal NFAT1 antibody before and after 10 min ionomycin stimulation with or without FK506 treatment. N = 3.



1018

1019

1020

1021

1022

1023

1024

1025

1026

1027

1028

1029

1030

1031

1032

1033

Fig. 2. NFAT1 deficiency in chondrocytes leads to an increased pro-survival and proinflammatory phenotype. A) Immunoblot of empty vector (EV)- and WT NFATC2transduced patient chondrocytes before and after 15min phorbol 12-myristate 13acetate/ionomycin (P/I) stimulation, 20ng/mL IL-1β stimulation, or no treatment. n=3. **B-D)** RNA-Seg carried out on EV- or WT *NFATC2*-transduced patient chondrocytes unstimulated or stimulated 24h with P/I or 20ng/mL IL-1\(\beta\). B) Venn diagram of significantly (FDR<0.05) (i) upregulated and (ii) downregulated genes in EV-transduced patient chondrocytes compared to WT *NFATC2*-transduced chondrocytes. **C)** Heatmap of top genes that meet a FDR<0.025 cutoff between EV and WT NFATC2-transduced patient chondrocytes. **D)** Heatmap of sample level enrichment scores (SLEA) scores with normalized enrichment scores (NES), p-val, and q-values for each pathway determined by gene set enrichment analysis (GSEA). Min and max refer to the rownormalized minimum and maximum for each pathway. E) Measurement of percent cell death in chondrocytes over 12 days by quantifying lactate dehydrogenase in supernatants. \*p<0.05, \*\*\*p<0.001 Two-way ANOVA, Dunnett's post-hoc test. F) ELISA detection of IL-6 production from the supernatants of chondrocytes in different conditions. \*p<0.05, \*\*\*p<0.001 Mann-Whitney U-test.




Fig. 3. NFAT1 deficiency leads to accumulation of hyperproliferative naïve B cells. A-C) Single cell RNA-Sequencing of peripheral blood mononuclear cells from the patient (II-1), heterozygous controls (n=3), and a healthy control (n=2) stimulated with P/I for 4h. A) Uniform manifold approximation and projection (UMAP) visualization of stimulated cell subsets. Cell labels indicated on right. B) Volcano plot showing differential gene expression in naïve B cells between patient and 5 healthy controls. Dark colors=significance, dim colors=nominal significance but not after adjusted p-value, grey colors=not significant. C) Violin plots of significantly differentially expressed genes of interest in naïve B cells comparing patient and healthy controls. D) Expression of NFAT1 in patient and control naïve B cells. Mean fluorescence intensities (MFIs) are indicated. E) Frequency of IgM++CD38++ transitional B cells in the patient (II-1) and heterozygous (n=4) and healthy controls (n=8). F) Quantification of E). G) Frequency of IgD+CD27 naïve (N) and IgD-CD27 memory (M) B cells in the patient and one representative control. Schematic of quadrants that correspond to each cell population and frequency shown top right. H,I) Quantification of G). J) Frequency of CD27<sup>+</sup>CD38<sup>+</sup> plasmablasts in mature CD19<sup>+</sup> B cells. **K)** IgD and IgM expression in each individual. MFIs are indicated. **I)** Frequency of Ki67<sup>+</sup> naïve B cells in the patient and a representative control. M) Quantification of I). N) Frequency of TNF- $\alpha^+$  naïve B cells in the patient and a representative control. O) Quantification of n). P-Q) Isolated naïve B cells from patient, heterozygous (n=1), and healthy controls (n=6) expanded for 6 days. P) Frequency of class-switched memory B cells and Q) plasmablasts before and after expansion. \*p<0.05, \*\*p<0.01. One-way ANOVA and Tukey's posthoc test. Green circles=healthy control, blue circle=II-2, blue upright triangle=I-2, blue inverted triangle=I-1, blue square=II-3, red diamond=II-1.

1035

1036

1037

1038

1039

1040

1041

1042

1043

1044

1045


1046

1047

1048

1049

1050



1054

1055

10561057

1058

1059

1060

1061

1062

1063

1064

1065

1066

1067

1068

1069

1070

1071

1072

1073

1074

1075

1076

1077

Fig. 4. NFAT1 deficiency impairs memory CD8<sup>+</sup> T cell function. A) Volcano plot showing differential gene expression in CD8<sup>+</sup> memory T cells between patient and 5 healthy controls (3 heterozygous controls, and 2 healthy controls). B) Violin plots of significantly differentially expressed genes of interest in CD8<sup>+</sup> memory T cells in patient and healthy controls. C) Frequency of CD8<sup>+</sup> T cell subsets in the patient and a representative control, including CD45RA<sup>+</sup>CD27<sup>-</sup> TEMRA, CD45RA<sup>+</sup>CD27<sup>+</sup> Naïve (N), CD45RA<sup>-</sup>CD27<sup>-</sup> effector memory (EM), CD45RA<sup>-</sup>CD27<sup>+</sup> central memory (CM). Quadrants corresponding to each subset shown top right. D) Quantification of C). E) Expression of NFAT1 in patient and control naïve and memory CD8<sup>+</sup> T cells. Mean fluorescence intensities (MFIs) are indicated. **F)** TNF-α and IFN-y expression in memory CD8<sup>+</sup> T cells in the patient and a control. **G**, **H**) Quantification of **F**). **I**) CD69 and PD-1 expression in patient and control memory CD8<sup>+</sup> T cells after 4h of P/I stimulation. MFIs are indicated. \*p<0.05, \*\*\*\*p<0.0001. One-way ANOVA and Tukey's post-hoc test. Green circles=healthy control, blue circle=II-2, blue upright triangle=I-2, blue inverted triangle=I-1, blue square=II-3, red diamond=II-1.






Fig. 5. Patient CD4<sup>+</sup> T cells are exhausted. A) Volcano plot showing differential gene expression in CD4<sup>+</sup> memory T cells between patient and 5 healthy controls. B) Violin plots of significantly differentially expressed genes of interest in CD4<sup>+</sup> memory T cells in patient and healthy controls. C) Frequency of CD8<sup>+</sup> T cell subsets in the patient and a representative control, including CD45RA<sup>+</sup>CD27<sup>-</sup> TEMRA, CD45RA<sup>+</sup>CD27<sup>+</sup> Naïve (N), CD45RA<sup>-</sup>CD27<sup>-</sup> effector memory (EM), CD45RA<sup>-</sup>CD27<sup>+</sup> central memory (CM). Quadrants corresponding to each subset shown top right. D) Quantification of C). E) Expression of NFAT1 in patient and control naïve and memory CD4<sup>+</sup> T cells. Mean fluorescence intensities are indicated. F) Frequency of T<sub>H</sub>1 (IFN-γ<sup>+</sup>IL-17A<sup>-</sup>), T<sub>H</sub>17 (IL-17A<sup>+</sup>IFN-γ<sup>+</sup>) cells in memory CD4<sup>+</sup> T cells of the patient and a representative control. G-H) Quantification of F). I) Frequency of T<sub>H</sub>2 (IL-4<sup>+</sup>IL-21<sup>-</sup>) and T<sub>FH</sub> (IL-21<sup>+</sup>IL-4<sup>-</sup>) cells in memory CD4<sup>+</sup> T cells of the patient and a representative control. J-K) Quantification of I). L) Frequency of TNF-α<sup>+</sup> and IL-2<sup>+</sup> CD4<sup>+</sup> memory T cells in the patient and a representative control. M,N) Quantification of L). \*p<0.05, \*\*p<0.01, \*\*\*\*p<0.001. One-way ANOVA and Tukey's post-hoc test. Green circles=healthy control, blue circle=II-2, blue upright triangle=I-2, blue inverted triangle=I-1, blue square=II-3, red diamond=II-1.




**Fig. 6. NFAT1 deficiency impairs T**<sub>FH</sub> **function. A)** Expression of activation markers in CD4<sup>+</sup> memory T cells after P/I treatment, including CD69, PD-1, CD40L, CD25 and ICOS. Mean fluorescence intensities (MFIs) are indicated. **B)** Frequency of circulating T<sub>FH</sub> (cT<sub>FH</sub>) cells in PD-1<sup>+</sup> memory CD4<sup>+</sup> T cells in the patient and a representative control. **C)** Quantification of **B)**. **D)** CD40L and IL-21 expression in patient and control cT<sub>FH</sub> cells after 4h P/I stimulation. **E,F)** Quantification of **D)**. **G)** Frequency of CD40L<sup>+</sup> and TNF-α<sup>+</sup> GFP<sup>+</sup> CD4<sup>+</sup> patient or control memory T cells after 4h P/I stimulation of EV or WT *NFATC2* transduction. **H,I)** Quantification of **G)**. \*p<0.05, \*\*p<0.01, \*\*\*\*p<0.001. One-way ANOVA and Tukey's post-hoc test. Green circles=healthy control, blue circle=II-2, blue upright triangle=I-2, blue inverted triangle=I-1, blue square=II-3, red diamond=II-1.

## Supplementary figures:


1104




**Supp Fig. 1. Extended B cell phenotyping. A)** Gating strategy for transitional B cells and plasmablasts in mature CD19<sup>+</sup> B cells. **B,C)** Quantification of IgD and IgM MFI in patient and control naïve B cells. **D)** Naïve B cells were isolated from patient and a control and expanded *in vitro*. Frequency of CD27<sup>+</sup>CD38<sup>-</sup> memory B cells was enumerated at Day 0 (Non-expanded) and Day 6 (Expanded). \*\*p<0.01. One-way ANOVA and Tukey's post-hoc test. Green circles=healthy control, blue circle=II-2, blue upright triangle=I-2, blue inverted triangle=I-1, blue square=II-3, red diamond=II-1.




**Supp Fig. 2. Extended CD8+ T cell phenotyping. A)** Frequency of IL-2<sup>+</sup> naïve CD8<sup>+</sup> T cells in the patient and a representative control. **B)** Quantification of **A)**. **C)** Frequency of IL-2<sup>+</sup> memory CD8<sup>+</sup> T cells in the patient and a representative control. **D)** Quantification of **C)**. **E)** CD40L expression in memory CD8<sup>+</sup> T cells. Mean fluorescence intensities are indicated. **F-H)** Quantification of **F)** CD40L<sup>+</sup>, **G)** CD69<sup>+</sup>, and **H)** PD-1<sup>+</sup> CD8<sup>+</sup> memory T cells. \*p<0.05, \*\*p<0.01. One-way ANOVA and Tukey's post-hoc test. Green circles=healthy control, blue circle=II-2, blue upright triangle=I-2, blue inverted triangle=I-1, blue square=II-3, red diamond=II-1.



Supp Fig. 3. Extended CD4<sup>+</sup> T cell immunophenotyping. A) Frequency of IFN-γ<sup>+</sup> and IL-17A<sup>+</sup> naïve CD4<sup>+</sup> T cells in the patient and a representative control. **B,C)** Quantification of **A)**. **D)** Frequency of IL-21<sup>+</sup> and IL-4<sup>+</sup> naïve CD4<sup>+</sup> T cells in the patient and a representative control. **E,F)** Quantification of **D)**. **G)** Frequency of TNF-α<sup>+</sup> and IL-2<sup>+</sup> naïve CD4<sup>+</sup> T cells in the patient and a representative control. **H,I)** Quantification of **G)**. **J)** naïve CD4<sup>+</sup> T cell expression of activation markers, including PD-1, CD40L, CD69, CD25, and ICOS. Mean fluorescence intensities (MFIs) are indicated. **K-O)** Frequency of same activation markers as in **J)**. **P-T)** Quantification of frequencies and MFIs of CD4<sup>+</sup> memory T cell activation markers, including PD-1, CD40L, CD69, CD25 and ICOS. \*p<0.05, \*\*p<0.01, \*\*\*p<0.001, \*\*\*\*p<0.0001. One-way ANOVA and Tukey's post-hoc test. Green circles=healthy control, blue circle=II-2, blue upright triangle=I-2, blue inverted triangle=I-1, blue square=II-3, red diamond=II-1.



**Supp Fig. 4. CD4<sup>+</sup> T cell gating strategies. A)** Gating strategy for circulating T follicular helper cells (T<sub>FH</sub>) defined as CD3<sup>+</sup>CD4<sup>+</sup>CD8<sup>-</sup>CD45RA<sup>-</sup>CXCR5<sup>+</sup>PD-1<sup>+</sup>. **B)** Gating strategy for identifying WT *NFATC2*-transduced CD4<sup>+</sup> memory T cells.



Supp Fig. 5. Patient T regulatory cell phenotype. A) Gating strategy for naïve and activated T regulatory cells (Treg) defined as CD3<sup>+</sup>CD4<sup>+</sup>CD8<sup>-</sup>CD25<sup>+</sup>CD127<sup>-</sup>FOXP3<sup>+</sup> and CD45RA<sup>+/-</sup>. B,C) Frequency of B) naïve and C) memory Tregs. D) Frequency of TNF-α<sup>+</sup> and IFN-γ<sup>+</sup> activated Tregs in the patient and a representative control. E,F) Quantification of D). G) Frequency of IL-2<sup>+</sup> activated Tregs in the patient and a representative control. H) Quantification of G). I-O) Quantification of Treg stability markers I) FOXP3 and J) Helios, and activation markers, K) CD25, L) CD69, M) CTLA4, N) ICOS, and O) PD-1 in activated Tregs. \*\*p<0.01. One-way ANOVA and Tukey's post-hoc test. Green circles=healthy control, red diamond=II-1.

## **Supplementary Tables:**

1145

1146

1147

## Supplementary Table 1: Gait and physical assessment in the patient

	Gait Assessment	Physical Assessment	
	Anterior pelvic tilt with adduction of thighs	Hip flexion contractures bilaterally, - 20°	
	Decreased dynamic hip range of motion	Decreased hip abduction, 5° right, 10° left	
Hip	Decreased hip extension in terminal stance	Decreased hip external rotation, neutral bilaterally	
	Hip flexion contractures	Decreased hip internal rotation, 25° right, 10° left	
		Positive Thomas test bilaterally	
		Positive Ober test bilaterally	
	Knee flexion contractures bilaterally with decreased popliteal angles	Knee flexion contractures bilaterally, -45° right, -30° left	
Knee	Increased knee flexion throughout stance	Popliteal angles; -70° right, -50° left	
	Incomplete knee flexion throughout terminal swing	Total range of motion for his left knee is approximately 30 -40°, and total range of motion for his right knee is approximately 90°	
Ankle	Decreased ankle dorsiflexion bilaterally	Decreased ankle dorsiflexion bilaterally; -10° with knee flexed, - 20° with knee extended	
	Sagittal joint powers are decreased at the ankle, left more than right		
	Absent first rocker bilaterally with abbreviated left second ankle rocker and aborted right second ankle rockers		
	Neutral foot progression angle on the frontal plane		
Foot	Mild left hind foot varus with forefoot pronation		
	Bilateral forefoot internal rotation		
	Pedobarography shows absent		
	hindfoot pressures bilaterally	Vary limited flavion and automaian of	
Upper limbs	Decreased arm swing	Very limited flexion and extension of both thumb MCPs and both wrists	
		limited extension, internal and	

		external rotation of his shoulders, as well as limited lateral flexion of the cervical spine
	Functional Mobility Scale (FMS), Ebrahim receives a score of 6 at 5 metres, 6 at 50 metres, and 6 at 500 metres	Demonstrates toe walking, worse on the right than on the left
Stride	Decreased step and stride lengths	When he gets from a sitting to standing position, he relies significantly on supports due to his contractures in his knees
	Mildly decreased velocity	
	Mild increased cadence	

1149

## **Supplementary Table 2:** Clinical Flow Cytometry for determination of T cell and B cell subset proportions in the patient along with reference intervals

1151

	Patient Results		Age-Specific Reference Interval
Lymphocyte T and B Cell Panel		0	
CD3 Cells	1.51	10 <sup>9</sup> /L	0.70-2.10
CD3 <sup>+</sup> CD4 <sup>+</sup> Cells	0.74	10 <sup>9</sup> /L	0.30-1.40
CD3 <sup>+</sup> CD8 <sup>+</sup> Cells	0.70	10 <sup>9</sup> /L	0.20-0.90
CD4:CD8 Ratio	1.05		1.00-3.60
CD19 <sup>+</sup> Cells	0.14	10 <sup>9</sup> /L	0.10-0.50
CD3 <sup>-</sup> CD56 <sup>+</sup> Cells	0.10	10 <sup>9</sup> /L	
T-Cell Naïve & Memory & Effector (CD27 and CD45RA) Subsets Panel			
CD4 <sup>+</sup> Naïve T-Cells (CD45RA <sup>+</sup> CCR7 <sup>+</sup> )	% of CD4 <sup>+</sup> T Cells	15.8	7.2-68.9
CD4 <sup>+</sup> Central Memory T-Cells (CD45RA <sup>-</sup> CCR7 <sup>+</sup> )	% of CD4 <sup>+</sup> T Cells	69.9	15.0-64.3
CD4 <sup>+</sup> Effector Memory T-Cells (CD45RA <sup>-</sup> CCR7 <sup>-</sup> )	% of CD4 <sup>+</sup> T Cells	13.6	4.9-43.6
CD4 <sup>+</sup> TEMRA T-Cells (CD45RA <sup>+</sup> CCR7 <sup>-</sup> )	% of CD4 <sup>+</sup> T Cells	0.7	<11.7
CD4 <sup>+</sup> CD57 <sup>+</sup> Cells	% of CD4 <sup>+</sup> T Cells	0.9	0.6-30.4
CD4 <sup>+</sup> PD1 <sup>+</sup> Cells	% of CD4 <sup>+</sup> T Cells	64.8	1.7-21.5
CD8 <sup>+</sup> Naïve T-Cells (CD45RA <sup>+</sup> CCR7 <sup>+</sup> )	% of CD8 <sup>+</sup> T Cells	20.5	2.6-72.4
CD8 <sup>+</sup> Central Memory T-Cells (CD45RA <sup>-</sup> CCR7 <sup>+</sup> )	% of CD8 <sup>+</sup> T Cells	14.1	2.7-36.2
CD8 <sup>+</sup> Effector Memory T-Cells (CD45RA <sup>-</sup> CCR7 <sup>-</sup> )	% of CD8 <sup>+</sup> T Cells	27.8	4.7-60.1

CD8 <sup>+</sup> TEMRA T-Cells (CD45RA <sup>+</sup> CCR7 <sup>-</sup> )	% of CD8 <sup>+</sup> T Cells	37.6	1.6-62.0
CD8 <sup>+</sup> CD57 <sup>+</sup> Cells	% of CD8 <sup>+</sup> T Cells	51.2	4.6-59.6
CD8 <sup>+</sup> PD1 <sup>+</sup> Cells	% of CD8 <sup>+</sup> T Cells	20.8	5.2-63.4
B-Cell Memory Subsets Panel			
Switched Memory B-Cells (CD27 <sup>+</sup> IgD <sup>-</sup> IgM-)	% of B Cells	0.2	4.6-35.5
Unswitched Memory B-Cells (CD27 <sup>+</sup> IgM <sup>+</sup> )	% of B Cells	4.6	1.9-23.7
Naïve B-Cells (CD27 <sup>-</sup> IgD <sup>+</sup> )	% of B Cells	93.7	17.9-75.1
Transitional B-Cells (CD27 <sup>-</sup> IgM <sup>+</sup> CD24 <sup>hi</sup> CD38 <sup>hi</sup> )	% of B Cells	15.7	0.1-6.3
CD21 <sup>low</sup> B Cells	% of B Cells	13.3	1.9-19.3